Christoph Sarrazin mainly investigates Hepatitis C virus, Virology, Internal medicine, Ribavirin and Immunology. His research in Hepatitis C virus intersects with topics in Viral hepatitis, Interferon, Hepatitis C and Genotype. His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Lamivudine and HBeAg.
His Gastroenterology study incorporates themes from Entecavir, Hepatitis B, Primary sclerosing cholangitis and Pathology. His research in the fields of Telaprevir and Pegylated interferon overlaps with other disciplines such as Protease inhibitor. His Liver disease research is multidisciplinary, relying on both Liver function and Cirrhosis.
Internal medicine, Virology, Hepatitis C virus, Gastroenterology and Ribavirin are his primary areas of study. His Internal medicine research includes themes of Chronic hepatitis and Sofosbuvir. His Hepatitis C virus study combines topics in areas such as Interferon, Hepatitis C and Genotype.
His Gastroenterology study also includes fields such as
His main research concerns Internal medicine, Gastroenterology, Hepatitis C virus, Virology and Genotype. He interconnects Ribavirin and Sofosbuvir in the investigation of issues within Internal medicine. The concepts of his Gastroenterology study are interwoven with issues in Hepatocellular carcinoma, Chronic hepatitis, Risk factor and Hepatitis B virus.
His Hepatitis C virus study improves the overall literature in Immunology. Christoph Sarrazin has researched Virology in several fields, including Promoter, Mutation and Antigen. His research integrates issues of Cell culture, Viral replication, Replicon and Host factor in his study of Genotype.
Christoph Sarrazin mostly deals with Internal medicine, Hepatitis C virus, Gastroenterology, Hepatitis C and Cirrhosis. His work carried out in the field of Internal medicine brings together such families of science as Ribavirin, Sofosbuvir and NS5A. The research on Immunology and Virology is part of his Hepatitis C virus project.
The study incorporates disciplines such as HBsAg, Hepatitis B virus, Polymorphism and Risk factor in addition to Gastroenterology. His studies in Hepatitis C integrate themes in fields like Hepatocellular carcinoma and Hepatitis. The Cirrhosis study combines topics in areas such as Sphingolipid, Single-nucleotide polymorphism, Case-control study and Fatty liver.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis
Mireen Friedrich-Rust;Mei-Fang Ong;Swantje Martens;Christoph Sarrazin.
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach;Stefan Zeuzem;Michael Manns;Ibrahim Altraif.
The Lancet Gastroenterology & Hepatology (2017)
Liver Fibrosis in Viral Hepatitis: Noninvasive Assessment with Acoustic Radiation Force Impulse Imaging versus Transient Elastography
Mireen Friedrich-Rust;Katrin Wunder;Susanne Kriener;Fariba Sotoudeh.
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Christoph Sarrazin;Stefan Zeuzem.
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Thomas Berg;Michael von Wagner;Samer Nasser;Christoph Sarrazin.
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
Devin Razavi-Shearer;Ivane Gamkrelidze;Mindie H Nguyen;Ding-Shinn Chen.
The Lancet Gastroenterology & Hepatology (2018)
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
Journal of Hepatology (2016)
Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis.
Mireen Friedrich-Rust;Mei-Fang Ong;Eva Herrmann;Volker Dries.
American Journal of Roentgenology (2007)
Treatment predictors of a sustained virologic response in hepatitis B and C
Annika Kau;Johannes Vermehren;Christoph Sarrazin.
Journal of Hepatology (2008)
SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders
Christoph Sarrazin;Christoph Sarrazin;Regine Rouzier;Frank Wagner;Nicole Forestier;Nicole Forestier.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: